p53 and p73 Expression in Esophageal Carcinoma Correlate with Clinicopathology of Tumors

被引:10
|
作者
Ye, Bing [2 ]
Wang, Xuefeng [1 ]
Yang, Zhenzhong [2 ]
Sun, Zhengping [2 ]
Zhang, Rongbo [1 ]
Hu, Youying [1 ]
Lu, Youguo [2 ]
Du, Jiuwei [1 ]
机构
[1] Anhui Univ Sci & Technol, Sch Med, Dept Lab Med, Huainan 232001, Peoples R China
[2] Xinhua Hosp Huainan City, Dept Oncol, Huainan, Peoples R China
基金
中国国家自然科学基金;
关键词
Esophageal cancer; p53; p73; Immunohistochemistry; Clinicopathological parameter; GENE;
D O I
10.5754/hge11964
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: Inactivation of tumor suppressors like p53 and p73 plays an important role in cancer initiation. We explored the clinical significance of p53 and p73 expression in esophageal carcinoma, along with their correlation with clinicopathological parameters of tumors for potential use in clinical evaluation of this disease. Methodology: In the present study, tumor samples and adjacent normal tissue samples were collected from 37 patients with esophageal cancer and the expression of p53 and p73 was detected by immunohistochemistry and correlated with clinicopathological parameters of tumors. Results: p53 and p73 were more frequently expressed in esophageal cancer than in adjacent normal tissue. Indeed, there was a positive car-relation between p53 and p73 expression and esophageal cancer (p<0.05). Analysis of clinicopathological features revealed that p53 expression was correlated with differentiation, distant metastases, and TNM stage (p<0.05) of tumors, but not with gender, age, infiltration depth, tumor size, or lymph node metastasis. In contrast, p73 expression was correlated only with distant metastases (p<0.05). Conclusions: Increased expression of p53 and p73 in esophageal carcinoma may serve as an indicator of tumor severity. Detection of these proteins in future studies may help understand the mechanisms of development, invasion and metastasis in esophageal cancer.
引用
收藏
页码:2192 / 2195
页数:4
相关论文
共 50 条
  • [41] Expression of p53, p63 and p73 isoforms in squamous cell carcinoma and in adenocarcinoma of esophagus:: Higher levels in tumors and especially in squamous cell carcinoma.
    Cui, RT
    de F, CC
    Martel-Planche, G
    Tanière, P
    Hainaut, P
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2003, 12 (11) : 1337S - 1337S
  • [42] Expression of the p53 homologues p63 and p73 in multiple simultaneous gastric cancer
    Tannapfel, A
    Schmelzer, S
    Benicke, M
    Klimpfinger, M
    Kohlhaw, K
    Mössner, J
    Engeland, K
    Wittekind, C
    JOURNAL OF PATHOLOGY, 2001, 195 (02): : 163 - 170
  • [43] p53/p63/p73 in the Epidermis in Health and Disease
    Botchkarev, Vladimir A.
    Flores, Elsa R.
    COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2014, 4 (08):
  • [44] P63 and p73: P53 mimics, menaces and more
    Yang, A
    McKeon, F
    NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2000, 1 (03) : 199 - 207
  • [45] p63 and p73: p53 mimics, menaces and more
    Annie Yang
    Frank McKeon
    Nature Reviews Molecular Cell Biology, 2000, 1 : 199 - 207
  • [46] On the shoulders of giants: p63, p73 and the rise of p53
    Yang, A
    Kaghad, M
    Caput, D
    McKeon, F
    TRENDS IN GENETICS, 2002, 18 (02) : 90 - 95
  • [47] Expression of PCNA and p53 in esophageal dysplasia and esophageal carcinoma
    Murakami, SI
    Uchida, Y
    Takeno, SS
    Noguchi, T
    Matsumoto, K
    Shimoda, H
    SURGERY TODAY-THE JAPANESE JOURNAL OF SURGERY, 1997, 27 (07): : 593 - 599
  • [48] P63 and P73 Activation in Cancers with p53 Mutation
    Cai, Bi-He
    Hsu, Yun-Chien
    Yeh, Fang-Yu
    Lin, Yu-Rou
    Lu, Rui-Yu
    Yu, Si-Jie
    Shaw, Jei-Fu
    Wu, Ming-Han
    Tsai, Yi-Zhen
    Lin, Ying-Chen
    Bai, Zhi-Yu
    Shih, Yu-Chen
    Hsu, Yi-Chiang
    Liao, Ruo-Yu
    Kuo, Wei-Hsin
    Hsu, Chao-Tien
    Lien, Ching-Feng
    Chen, Chia-Chi
    BIOMEDICINES, 2022, 10 (07)
  • [49] Transactivation-deficient p73α (p73Δexon2) inhibits apoptosis and competes with p53
    Fillippovich, I
    Sorokina, N
    Gatei, M
    Haupt, Y
    Hobson, K
    Moallem, E
    Spring, K
    Mould, M
    McGuckin, MA
    Lavin, MF
    Khanna, KK
    ONCOGENE, 2001, 20 (04) : 514 - 522
  • [50] Transactivation-deficient p73α (p73Δexon2) inhibits apoptosis and competes with p53
    Igor Fillippovich
    Natasha Sorokina
    Magtouf Gatei
    Ygal Haupt
    Karen Hobson
    Eli Moallem
    Kevin Spring
    Michelle Mould
    Michael A McGuckin
    Martin F Lavin
    Kum Kum Khanna
    Oncogene, 2001, 20 : 514 - 522